Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on April 26, 2007

Arteriosclerosis, Thrombosis, and Vascular Biology. 2007
Published online before print April 26, 2007, doi: 10.1161/ATVBAHA.107.143248
A more recent version of this article appeared on July 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/7/1651    most recent
ATVBAHA.107.143248v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robinson, S. D.
Right arrow Articles by Newby, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robinson, S. D.
Right arrow Articles by Newby, D. E.
Related Collections
Right arrow Chronic ischemic heart disease

Submitted on January 2, 2007
Accepted on April 12, 2007

Endothelial Fibrinolytic Capacity Predicts Future Adverse Cardiovascular Events in Patients With Coronary Heart Disease

Simon D. Robinson *; Christopher A. Ludlam ; Nicholas A. Boon ; and David E. Newby

From the Centre for Cardiovascular Sciences (S.D.R., D.E.N.), University of Edinburgh, the Department of Haematology (C.A.L.), Royal Infirmary of Edinburgh, and the Department of Cardiology (N.A.B., D.E.N.), Royal Infirmary of Edinburgh, UK.

* To whom correspondence should be addressed. E-mail: simon.robinson{at}ed.ac.uk.

Objective--The endothelium-derived fibrinolytic factor tissue plasminogen activator (t-PA) is a major determinant of vessel patency after coronary plaque rupture and thrombosis. We assessed whether endothelial fibrinolytic capacity predicts atherothrombotic events in patients with coronary heart disease.

Methods and Results--Plasma t-PA and plasminogen activator inhibitor (PAI)-1 concentrations were measured during intrabrachial substance P infusion in 98 patients with angiographically proven stable coronary heart disease. Forearm blood flow was measured during infusion of substance P and sodium nitroprusside. Cardiovascular events (cardiovascular death, myocardial infarction [MI], ischemic stroke [CVA], and emergency hospitalization for unstable angina) were determined during 42 months of follow-up. Patients experiencing a cardiovascular event (n=19) had similar baseline characteristics to those free of events. Substance P caused a dose-dependent increase in plasma t-PA concentrations (P<0.001). However, net t-PA release was 72% lower in the patients who experienced death, MI, or CVA, and 48% lower in those who suffered death, MI, CVA or hospitalization for unstable angina (P<0.05). Major adverse cardiovascular events were most frequent in those with the lowest fibrinolytic capacity (P=0.03 for trend); patients with the lowest quartile of t-PA release had the highest rate of adverse events (P=0.01).

Conclusion--Endothelial fibrinolytic capacity, as measured by stimulated t-PA release, predicts the future risk of adverse cardiovascular events in patients with coronary heart disease. We suggest that endothelial fibrinolytic capacity is a powerful novel determinant of cardiovascular risk.


Key words: coronary heart disease • endothelium • fibrinolysis • survival • vasodilation




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
J. D. Maclay, D. A. McAllister, N. L. Mills, F. P. Paterson, C. A. Ludlam, E. M. Drost, D. E. Newby, and W. MacNee
Vascular Dysfunction in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., September 15, 2009; 180(6): 513 - 520.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Giannarelli, A. Virdis, F. De Negri, A. Magagna, E. Duranti, A. Salvetti, and S. Taddei
Effect of Sulfaphenazole on Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients
Circulation, March 31, 2009; 119(12): 1625 - 1633.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Giannarelli, A. Virdis, F. De Negri, E. Duranti, A. Magagna, L. Ghiadoni, A. Salvetti, and S. Taddei
Tissue-Type Plasminogen Activator Release in Healthy Subjects and Hypertensive Patients: Relationship With {beta}-Adrenergic Receptors and the Nitric Oxide Pathway
Hypertension, August 1, 2008; 52(2): 314 - 321.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
G. P. Van Guilder, G. L. Hoetzer, J. J. Greiner, B. L. Stauffer, and C. A. DeSouza
Acute and chronic effects of vitamin C on endothelial fibrinolytic function in overweight and obese adult humans
J. Physiol., July 15, 2008; 586(14): 3525 - 3535.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. N. Lang, I. J. Guthmundsdottir, N. A. Boon, C. A. Ludlam, K. A. Fox, and D. E. Newby
Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers smoking, thrombin, and vascular responses in vivo.
J. Am. Coll. Cardiol., July 1, 2008; 52(1): 33 - 39.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Pretorius, G. P. van Guilder, R. J. Guzman, J. M. Luther, and N. J. Brown
17{beta}-Estradiol Increases Basal but Not Bradykinin-Stimulated Release of Active t-PA in Young Postmenopausal Women
Hypertension, April 1, 2008; 51(4): 1190 - 1196.
[Abstract] [Full Text] [PDF]